DK2178921T3 - Monoclonal antibodies to glypican 3 - Google Patents

Monoclonal antibodies to glypican 3 Download PDF

Info

Publication number
DK2178921T3
DK2178921T3 DK08796249.4T DK08796249T DK2178921T3 DK 2178921 T3 DK2178921 T3 DK 2178921T3 DK 08796249 T DK08796249 T DK 08796249T DK 2178921 T3 DK2178921 T3 DK 2178921T3
Authority
DK
Denmark
Prior art keywords
antibody
seq
glypican
antibodies
human
Prior art date
Application number
DK08796249.4T
Other languages
Danish (da)
English (en)
Inventor
Jonathan Alexander Terrett
Li-Sheng Lu
Haichun Huang
Dapeng Yao
Chin Pan
Heidi Leblanc
Timothy Sproul
Mark Yamanaka
Original Assignee
Squibb & Sons Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Squibb & Sons Llc filed Critical Squibb & Sons Llc
Application granted granted Critical
Publication of DK2178921T3 publication Critical patent/DK2178921T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Engineering & Computer Science (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
DK08796249.4T 2007-07-17 2008-07-17 Monoclonal antibodies to glypican 3 DK2178921T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95984507P 2007-07-17 2007-07-17
PCT/US2008/070344 WO2009012394A1 (en) 2007-07-17 2008-07-17 Monoclonal antibodies against glypican-3

Publications (1)

Publication Number Publication Date
DK2178921T3 true DK2178921T3 (en) 2016-04-04

Family

ID=39874207

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08796249.4T DK2178921T3 (en) 2007-07-17 2008-07-17 Monoclonal antibodies to glypican 3

Country Status (18)

Country Link
US (2) US8680247B2 (enExample)
EP (1) EP2178921B1 (enExample)
JP (2) JP5868593B2 (enExample)
KR (2) KR101527342B1 (enExample)
CN (1) CN101815726B (enExample)
AU (1) AU2008275985B2 (enExample)
CY (1) CY1117236T1 (enExample)
DK (1) DK2178921T3 (enExample)
ES (1) ES2562790T3 (enExample)
HR (1) HRP20160270T1 (enExample)
HU (1) HUE028737T2 (enExample)
ME (1) ME02345B (enExample)
MX (1) MX2010000537A (enExample)
PL (1) PL2178921T3 (enExample)
PT (1) PT2178921E (enExample)
RS (1) RS54624B1 (enExample)
SI (1) SI2178921T1 (enExample)
WO (1) WO2009012394A1 (enExample)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101198698B (zh) 2005-03-31 2014-03-19 中外制药株式会社 通过调节多肽缔合制备多肽的方法
CN104761637B (zh) 2006-03-31 2021-10-15 中外制药株式会社 调控抗体血液动力学的方法
DK2178921T3 (en) * 2007-07-17 2016-04-04 Squibb & Sons Llc Monoclonal antibodies to glypican 3
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
EP2196541B1 (en) * 2007-09-28 2012-11-07 Chugai Seiyaku Kabushiki Kaisha Anti-glypican-3 antibody having improved kinetics in plasma
CL2009000647A1 (es) * 2008-04-04 2010-06-04 Chugai Pharmaceutical Co Ltd Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto.
SG175891A1 (en) * 2009-05-08 2011-12-29 Genentech Inc Humanized anti-egfl7 antibodies and methods using same
US9260492B2 (en) 2010-11-15 2016-02-16 Pieris Ag Muteins of human lipocalin 2 with affinity for glypican-3 (GPC-3)
TWI638833B (zh) 2010-11-30 2018-10-21 中外製藥股份有限公司 細胞傷害誘導治療劑
MY163081A (en) * 2010-12-28 2017-08-15 Chugai Pharmaceutical Co Ltd Animal cell culturing method
WO2012145469A1 (en) 2011-04-19 2012-10-26 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human monoclonal antibodies specific for glypican-3 and use thereof
US8852599B2 (en) 2011-05-26 2014-10-07 Bristol-Myers Squibb Company Immunoconjugates, compositions for making them, and methods of making and use
US20140322216A1 (en) * 2011-11-08 2014-10-30 The Trustees Of The University Of Pennsylvania Glypican-3-specific antibody and uses thereof
US9409994B2 (en) 2012-06-01 2016-08-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services High-affinity monoclonal antibodies to glypican-3 and use thereof
CN103833852A (zh) * 2012-11-23 2014-06-04 上海市肿瘤研究所 针对磷脂酰肌醇蛋白多糖-3和t细胞抗原的双特异性抗体
LT2956173T (lt) 2013-02-14 2017-06-26 Bristol-Myers Squibb Company Tubulizino junginiai, gavimo ir panaudojimo būdai
KR20160068738A (ko) 2013-08-14 2016-06-15 윌리엄 마쉬 라이스 유니버시티 운시알라마이신의 유도체, 합성 방법 및 항종양 제제로서 이들의 용도
CN105764922B (zh) 2013-09-27 2020-07-17 中外制药株式会社 多肽异源多聚体的制备方法
US10093746B2 (en) 2014-09-04 2018-10-09 The Trustees Of The University Of Pennsylvania Glypican-3 antibody and uses thereof
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
US10077287B2 (en) 2014-11-10 2018-09-18 Bristol-Myers Squibb Company Tubulysin analogs and methods of making and use
PL3221346T3 (pl) 2014-11-21 2021-03-08 Bristol-Myers Squibb Company Przeciwciała ze zmodyfikowanym regionem stałym łańcucha ciężkiego
CN104829704B (zh) * 2014-12-15 2016-08-17 河北省科学院生物研究所 一种磷脂酰肌醇蛋白聚糖gpc3蛋白片段及其应用和制备的杂交瘤细胞株
MX2017009145A (es) 2015-01-14 2017-11-22 Bristol Myers Squibb Co Dimeros de benzodiazepina, conjugados de estos, y sus metodos de preparacion y uso.
KR20170102981A (ko) 2015-01-14 2017-09-12 브리스톨-마이어스 스큅 컴퍼니 헤테로아릴렌-가교된 벤조디아제핀 이량체, 그의 접합체, 및 제조 및 사용 방법
US11142587B2 (en) 2015-04-01 2021-10-12 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide hetero-oligomer
CN105037540A (zh) * 2015-05-13 2015-11-11 北京比洋生物技术有限公司 抗磷脂酰肌醇蛋白聚糖3全人源抗体
RU2754466C2 (ru) 2015-05-18 2021-09-02 ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ Слитый полипептид с противораковой активностью
US10273275B2 (en) 2015-05-18 2019-04-30 Pieris Pharmaceuticals Gmbh Muteins of human lipocalin 2 with affinity for glypican-3 (GPC3) and methods of use thereof
JP6762485B2 (ja) * 2015-06-24 2020-09-30 学校法人慶應義塾 抗グリピカン−１−免疫抗原受容体
US12168061B2 (en) * 2015-08-03 2024-12-17 Crage Medical Co., Limited Antibody against glypican-3 and application thereof
KR101796688B1 (ko) 2015-10-29 2017-12-01 재단법인 목암생명과학연구소 신규 항-글리피칸 3 항체 및 이를 포함하는 약학적 조성물
US20180362619A1 (en) 2015-12-21 2018-12-20 Bristol-Myers Squibb Company Variant antibodies for site-specific conjugation
CN105717303A (zh) * 2016-01-29 2016-06-29 山东康力医疗器械科技有限公司 一种用荧光免疫层析法检测磷酯酰肌醇蛋白聚糖3的方法及其试剂盒
CA3016424A1 (en) 2016-03-14 2017-09-21 Chugai Seiyaku Kabushiki Kaisha Cell injury inducing therapeutic drug for use in cancer therapy
US20170326249A1 (en) * 2016-05-10 2017-11-16 Bristol-Myers Squibb Company Antibody-drug conjugate of an anti-glypican-3 antibody and a tubulysin analog, preparation and uses
US10994033B2 (en) 2016-06-01 2021-05-04 Bristol-Myers Squibb Company Imaging methods using 18F-radiolabeled biologics
CN106084041A (zh) * 2016-06-24 2016-11-09 安徽未名细胞治疗有限公司 一种全人源抗GPC3的全分子IgG抗体及其应用
AU2017301826A1 (en) 2016-07-26 2019-03-14 Tessa Therapeutics Ltd. Chimeric antigen receptor
ES2902179T3 (es) 2016-08-19 2022-03-25 Bristol Myers Squibb Co Compuestos de seco-ciclopropapirroloindol, conjugados de anticuerpo-fármaco de los mismos y métodos de elaboración y uso
WO2018075842A1 (en) 2016-10-20 2018-04-26 Bristol-Myers Squibb Company Condensed benzodiazepine derivatives and conjugates made therefrom
IL270138B2 (en) * 2017-04-26 2025-08-01 Eureka Therapeutics Inc Structures that specifically recognize glypican 3 and their uses
US20200299400A1 (en) 2017-05-25 2020-09-24 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
CN109988240B (zh) * 2017-12-29 2022-06-28 安源医药科技（上海）有限公司 抗gpc-3抗体及其用途
SG11202011739SA (en) 2018-05-29 2020-12-30 Bristol Myers Squibb Co Modified self-immolating moieties for use in prodrugs and conjugates and methods of using and making
CA3117212A1 (en) 2018-10-23 2020-04-30 Dragonfly Therapeutics, Inc. Heterodimeric fc-fused proteins
JP2022513653A (ja) 2018-11-28 2022-02-09 ブリストル－マイヤーズ スクイブ カンパニー 修飾された重鎖定常領域を含む抗体
KR102861586B1 (ko) 2018-11-30 2025-09-17 브리스톨-마이어스 스큅 컴퍼니 글루타민-함유 경쇄 c-말단 연장부를 포함하는 항체, 그의 접합체, 및 방법 및 용도
JP7514836B2 (ja) 2018-12-12 2024-07-11 ブリストル－マイヤーズ スクイブ カンパニー トランスグルタミナーゼによるコンジュゲーションのための改変抗体、ならびにそのコンジュゲート、方法および用途
EP3941942A4 (en) * 2019-03-21 2023-04-26 Agency For Science, Technology And Research COMPOSITION
CN116063528A (zh) * 2019-08-16 2023-05-05 原启生物科技(上海)有限责任公司 一种分离的抗原结合蛋白及其用途
EP4138778A1 (en) 2020-04-22 2023-03-01 Dragonfly Therapeutics, Inc. Formulation, dosage regimen, and manufacturing process for heterodimeric fc-fused proteins
CN115515981A (zh) * 2020-05-07 2022-12-23 凡恩世制药公司 抗肿瘤相关抗原抗体及其用途
TW202241947A (zh) 2020-12-18 2022-11-01 比利時商艾伯霖克斯公司 包含靶向磷脂醯肌醇蛋白聚糖—３和ｔ細胞受體的免疫球蛋白單可變結構域的多肽
WO2022223018A1 (en) * 2021-04-23 2022-10-27 Shanghai Henlius Biotech, Inc. Anti-gpc3 antibodies and methods of use
CN113354737B (zh) * 2021-07-20 2022-11-18 广州爱思迈生物医药科技有限公司 一种磷脂酰肌醇蛋白聚糖3抗体及其应用
WO2023023354A2 (en) * 2021-08-19 2023-02-23 Adicet Therapeutics, Inc. Methods for detection of membrane bound glypican-3
WO2023061505A1 (en) * 2021-10-15 2023-04-20 Concept To Medicine Biotech Co., Ltd. Anti-glypican 3 antibodies
CN120344270A (zh) 2022-10-07 2025-07-18 Ambrx 公司 药物接头及其抗体缀合物
WO2024094017A1 (zh) * 2022-11-01 2024-05-10 上海齐鲁制药研究中心有限公司 一种针对磷脂酰肌醇蛋白聚糖3的双特异性抗体及其应用
TW202506733A (zh) 2023-06-12 2025-02-16 美商安進公司 淋巴毒素β受體促效劑結合蛋白

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3426001B2 (ja) 1993-09-16 2003-07-14 東芝機械株式会社 ステージ内蔵型雰囲気室装置
EP0822830B1 (en) * 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
EP1411118B1 (en) * 2001-06-22 2008-09-03 Chugai Seiyaku Kabushiki Kaisha Cell proliferation inhibitors containing anti-glypican-3 antibody
WO2004022597A1 (ja) * 2002-09-04 2004-03-18 Chugai Seiyaku Kabushiki Kaisha Gpc3の血中可溶化ｎ端ﾍﾟﾌﾟﾁﾄﾞに対する抗体
WO2004022595A1 (ja) 2002-09-04 2004-03-18 Chugai Seiyaku Kabushiki Kaisha MRL/lprマウスを用いた抗体の作製
AU2002330482A1 (en) 2002-09-04 2004-03-29 Perseus Proteomics Inc. Method of diagnosing cancer by detecting gpc3
WO2004067571A1 (fr) 2003-01-30 2004-08-12 Wu, Mengchao Anticorps monoclonal contre l'hepatome humain et utilisation de celui-ci
CN100555588C (zh) 2003-06-27 2009-10-28 日本电气株式会社 薄膜晶体管、薄膜晶体管基板、电子设备及多晶半导体薄膜的制造方法
CA2544692C (en) * 2004-07-09 2014-04-01 Chugai Seiyaku Kabushiki Kaisha Anti-glypican 3 antibody
KR101300546B1 (ko) 2004-08-24 2013-09-02 추가이 세이야쿠 가부시키가이샤 항 글리피칸 3 항체를 이용한 어쥬번트 요법
AU2005297772B2 (en) 2004-10-26 2011-06-23 Chugai Seiyaku Kabushiki Kaisha Anti-glypican 3 antibody having modified sugar chain
DE602005027258D1 (de) * 2005-03-14 2011-05-12 Us Gov Health & Human Serv Humane monoklonale antikörper gegen hendra- und nipah-viren
CA2612241C (en) * 2005-07-01 2018-11-06 Medarex, Inc. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
US7744800B2 (en) 2006-01-06 2010-06-29 Molded Fiber Glass Companies Method and apparatus for controlling the stacking height of stackable products during compression molding off stops
EP2097097B1 (en) * 2006-12-01 2018-05-30 E. R. Squibb & Sons, L.L.C. Antibodies, in particular human antibodies, that bind cd22 and uses thereof
DK2178921T3 (en) * 2007-07-17 2016-04-04 Squibb & Sons Llc Monoclonal antibodies to glypican 3
US8852599B2 (en) * 2011-05-26 2014-10-07 Bristol-Myers Squibb Company Immunoconjugates, compositions for making them, and methods of making and use

Also Published As

Publication number Publication date
ES2562790T3 (es) 2016-03-08
JP5868593B2 (ja) 2016-02-24
HUE028737T2 (en) 2017-01-30
EP2178921B1 (en) 2016-01-06
ME02345B (me) 2016-08-31
PL2178921T3 (pl) 2016-06-30
US20140186892A1 (en) 2014-07-03
PT2178921E (pt) 2016-03-23
CN101815726B (zh) 2013-04-03
CN101815726A (zh) 2010-08-25
JP2010533498A (ja) 2010-10-28
JP2014236734A (ja) 2014-12-18
US8680247B2 (en) 2014-03-25
CY1117236T1 (el) 2017-04-05
AU2008275985A1 (en) 2009-01-22
WO2009012394A1 (en) 2009-01-22
SI2178921T1 (sl) 2016-05-31
KR101527342B1 (ko) 2015-06-09
US20100209432A1 (en) 2010-08-19
AU2008275985B2 (en) 2013-09-19
RS54624B1 (sr) 2016-08-31
EP2178921A1 (en) 2010-04-28
MX2010000537A (es) 2010-03-25
KR20100056467A (ko) 2010-05-27
HRP20160270T1 (hr) 2016-05-06
KR20150038732A (ko) 2015-04-08
KR101570252B1 (ko) 2015-11-19
US9217033B2 (en) 2015-12-22

Similar Documents

Publication Publication Date Title
US20260028416A1 (en) Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1 antibodies
EP2178921B1 (en) Monoclonal antibodies against glypican-3
AU2006321841B2 (en) Human monoclonal antibodies to protein tyrosine kinase 7 ( PTK7 ) and their use
AU2012241084B2 (en) Human monoclonal antibodies to fucosyl-GM1 and methods for using anti-fucosyl-GM1
AU2013257387A1 (en) Monoclonal antibodies against glypican-3
HK1124622B (en) Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1
BRPI0620553B1 (pt) Anticorpo monoclonal humano isolado ou uma porção ligante ao antígeno do mesmo, composição e imunoconjugado
AU2013202283A1 (en) Human monoclonal antibodies to fucosyl-GM1 and methods for using anti-fucosyl GM1